Zyus Life Sciences Corp ZLSCF

$0.60 0.00 (-0.02%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$0
P/E (trailing)
—
P/E (forward)
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
200
Avg volume
4,516
Day's range
$0.60 – $0.60
Shares out
—
Stochastic %K
88%
Beta
—
Analysts
—
Price target
—

Price

Company profile

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, th...

Show more

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
888 651 9987
Website
https://www.zyus.com
Address
Unit 204, 407 Downey Road, Saskatoon, Canada

Latest news

No headlines yet.